Related references
Note: Only part of the references are listed.Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples
Chunhua Ma et al.
THORACIC CANCER (2020)
Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
James R. Patrinely et al.
CANCER (2020)
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Jenny H. Lee et al.
CLINICAL CANCER RESEARCH (2020)
Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis
Teresa Gerber et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela et al.
CLINICAL CANCER RESEARCH (2020)
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Jonathan C. M. Wan et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles
Carlos Aya-Bonilla et al.
CANCERS (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Bradon R. McDonald et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
How liquid biopsies can change clinical practice in oncology
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
Leslie Calapre et al.
MOLECULAR ONCOLOGY (2019)
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Ashleigh C. McEvoy et al.
BMC CANCER (2018)
Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy
Verena Haselmann et al.
CLINICAL CHEMISTRY (2018)
Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease
Leomar Y. Ballester et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting
Steven P. Rowe et al.
MOLECULAR ONCOLOGY (2018)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis
David Stephenson et al.
ONCOTARGET (2017)
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials
Georgina V. Long et al.
JAMA ONCOLOGY (2017)
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Ademi Santiago-Walker et al.
CLINICAL CANCER RESEARCH (2016)
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review
Francesco Spagnolo et al.
CANCER TREATMENT REVIEWS (2016)
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
Max Schreuer et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies
Parisa Momtaz et al.
ONCOTARGET (2016)
F-18-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis
Powell Perng et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2015)
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda et al.
NATURE COMMUNICATIONS (2015)
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
Elin S. Gray et al.
ONCOTARGET (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Double-stranded DNA in exosomes: a novel biomarker in cancer detection
Caitlin Williams et al.
CELL RESEARCH (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα
Michael P. Smith et al.
CANCER DISCOVERY (2014)
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma
Tae Min Kim et al.
CANCER (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non-Small Cell Lung Cancer
Helen H. W. Chen et al.
RADIOLOGY (2012)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis
Yan Xing et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Testing the ratio of two Poisson rates
Kangxia Gu et al.
BIOMETRICAL JOURNAL (2008)
Consecutive patients diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma:: Experience with 250 consecutive patients
MJ Reinhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The treatment of brain metastases in melanoma patients
D Bafaloukos et al.
CANCER TREATMENT REVIEWS (2004)
Share Paper
